Cancer doesn’t evolve by pure chaos. Scientists have developed a powerful new method that reveals the hidden rules guiding how cancer cells gain and lose whole chromosomes—massive genetic shifts that ...

For almost 60 years, scientists have tried to understand why DNA doesn't replicate wildly and uncontrollably every time a ...

New study shows that aggressive cancer cells can be identified in a simple, new way; by how they physically behave, not just by their genes. Using specially textured Meta surfaces pattered with tiny ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

Researchers at Moffitt Cancer Center have developed a new way to predict how cancer cells evolve by gaining and losing whole ...

A new study reveals a simple and fast, label-free way to distinguish aggressive cancer cells by how they physically behave.

Varun Venkataramani is the winner of the 2025 Eppendorf Award for Young European Investigators. A neurologist and group leader at Heidelberg University Hospital, Germany, his work in cancer ...

Scientists at LSU have patented a novel way to kill cancer cells using staph bacteria, sometimes called the “superbug.” ...

Microbiologist John van der Oost of Wageningen University & Research (WUR) has received an ERC Proof of Concept grant to further develop a promising CRISPR-based approach to cancer treatment. With ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...